BSE Live
Jan 02, 16:01Prev. Close
6342.60
Open Price
6342.90
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Jan 02, 15:56Prev. Close
6344.00
Open Price
6351.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
6392.50 (44)
| Balance Sheet of Divis Laboratories (in Rs. Cr.) | Mar 15 | Mar 14 | Mar 13 | Mar 12 | Mar 11 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| EQUITIES AND LIABILITIES | ||||||
| SHAREHOLDER'S FUNDS | ||||||
| Equity Share Capital | 26.55 | 26.55 | 26.55 | 26.55 | 26.52 | |
| Total Share Capital | 26.55 | 26.55 | 26.55 | 26.55 | 26.52 | |
| Reserves and Surplus | 3,468.81 | 2,936.80 | 2,474.05 | 2,104.98 | 1,770.96 | |
| Total Reserves and Surplus | 3,468.81 | 2,936.80 | 2,474.05 | 2,104.98 | 1,770.96 | |
| Total Shareholders Funds | 3,495.36 | 2,963.35 | 2,500.60 | 2,131.52 | 1,797.48 | |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| NON-CURRENT LIABILITIES | ||||||
| Long Term Borrowings | 1.05 | 1.55 | 2.10 | 2.56 | 4.92 | |
| Deferred Tax Liabilities [Net] | 126.22 | 115.00 | 79.22 | 60.89 | 50.04 | |
| Other Long Term Liabilities | 0.00 | 0.00 | 0.00 | 6.25 | 9.62 | |
| Long Term Provisions | 6.99 | 3.18 | 2.39 | 1.65 | 2.82 | |
| Total Non-Current Liabilities | 134.26 | 119.74 | 83.71 | 71.35 | 67.39 | |
| CURRENT LIABILITIES | ||||||
| Short Term Borrowings | 25.07 | 16.32 | 30.51 | 50.20 | 13.62 | |
| Trade Payables | 226.87 | 151.70 | 160.44 | 159.54 | 123.00 | |
| Other Current Liabilities | 203.45 | 147.80 | 130.08 | 135.83 | 105.35 | |
| Short Term Provisions | 320.14 | 311.58 | 233.42 | 208.21 | 167.92 | |
| Total Current Liabilities | 775.53 | 627.41 | 554.45 | 553.78 | 409.90 | |
| Total Capital And Liabilities | 4,405.15 | 3,710.49 | 3,138.76 | 2,756.66 | 2,274.78 | |
| ASSETS | ||||||
| NON-CURRENT ASSETS | ||||||
| Tangible Assets | 1,304.94 | 1,221.84 | 908.72 | 738.42 | 589.93 | |
| Intangible Assets | 3.95 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Capital Work-In-Progress | 218.18 | 144.48 | 303.41 | 181.58 | 103.72 | |
| Fixed Assets | 1,527.08 | 1,366.33 | 1,212.13 | 920.40 | 694.27 | |
| Non-Current Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Deferred Tax Assets [Net] | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long Term Loans And Advances | 105.67 | 71.18 | 62.52 | 81.38 | 36.11 | |
| Other Non-Current Assets | 0.00 | 0.00 | 0.00 | 3.93 | 3.69 | |
| Total Non-Current Assets | 1,632.75 | 1,437.51 | 1,274.65 | 1,005.71 | 734.07 | |
| CURRENT ASSETS | ||||||
| Current Investments | 733.00 | 501.88 | 407.81 | 477.04 | 525.64 | |
| Inventories | 1,162.64 | 932.42 | 835.69 | 678.96 | 571.71 | |
| Trade Receivables | 741.64 | 723.70 | 512.00 | 495.58 | 365.23 | |
| Cash And Cash Equivalents | 65.22 | 40.51 | 40.89 | 30.94 | 17.67 | |
| Short Term Loans And Advances | 60.66 | 68.37 | 61.04 | 65.51 | 59.02 | |
| OtherCurrentAssets | 9.23 | 6.11 | 6.68 | 2.92 | 1.44 | |
| Total Current Assets | 2,772.40 | 2,272.99 | 1,864.11 | 1,750.95 | 1,540.71 | |
| Total Assets | 4,405.15 | 3,710.49 | 3,138.76 | 2,756.66 | 2,274.78 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| CONTINGENT LIABILITIES, COMMITMENTS | ||||||
| Contingent Liabilities | 231.30 | 221.65 | 222.35 | 300.37 | 297.07 | |
| BONUS DETAILS | ||||||
| Bonus Equity Share Capital | 13.12 | 13.12 | 13.12 | 13.12 | 13.12 | |
| NON-CURRENT INVESTMENTS | ||||||
| Non-Current Investments Quoted Market Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Current Investments Unquoted Book Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| CURRENT INVESTMENTS | ||||||
| Current Investments Quoted Market Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Current Investments Unquoted Book Value | 733.00 | 501.88 | 407.81 | 477.04 | 525.73 |
20.11.2025
Accumulate Divis Laboratories; target of Rs 6795: Deven Choksey
14.11.2025
Divis Labs Consolidated September 2025 Net Sales at Rs 2,715.00 crore, up 16.12% Y-o-Y
12.11.2025
Neutral Divis Laboratories; target of Rs 6925: Motilal Oswal
12.11.2025
Divis Labs Standalone September 2025 Net Sales at Rs 2,660.00 crore, up 15.55% Y-o-Y
24.05.2024
Divi's Labs Q4 preview: Revenue, net profit to grow on normalised base, better product mix
04.11.2023
Divi's Labs Q2 Preview: Earnings likely to improve sequentially on better margins, product mix
14.08.2023
Divi's Labs Q1 Preview: Base effect to pressure earnings, brokerages predict sequential recovery
19.05.2023
Divi's Labs Preview: Unfavourable base, elevated input costs to turn Q4 a sour pill